| Project/Area Number |
26462043
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Wada Hiroshi 大阪大学, 医学系研究科, 助教 (00572554)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
永野 浩昭 山口大学, 医学(系)研究科(研究院), 教授 (10294050)
小林 省吾 地方独立行政法人大阪府立病院機構大阪国際がんセンター(研究所), その他部局等, 副部長 (30452436)
富丸 慶人 大阪大学, 医学系研究科, 助教 (70528570)
江口 英利 大阪大学, 医学系研究科, 准教授 (90542118)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 肝細胞癌 / 血管新生 / エクソソーム / マイクロRNA |
|---|
| Outline of Final Research Achievements |
We aim to clarify function of exosomes secreted from hepatocellular carcinoma (HCC) cells under hypoxia to angiogenesis. Two human HCC cell lines (PLC/PRF/5 and HuH7) and human umbilical vein endothelial cells (HUVECs) were used. Exosomes derived from HCC cells were added to HUVECs and we evaluate their angiogenic activity. We also evaluated the expression of miR-155 in the exosomes from 40 patients with HCC. Exosomes under hypoxia remarkably enhanced tube formation of HUVECs, compared with exosomes under normxia or control. Both cellular and exosomal miR-155 was significantly up-regulated under hypoxic conditions. Knockdown of miR-155 in HCC cells attenuated the promotion of tube formation by exosomes under hypoxia. High expression of exosomal miR-155 was significantly correlated with early recurrence. These results suggest that exosomes derived from HCC cells under hypoxia promotes angiogenesis, and that exosomal miR-155 may be target of molecular therapy for HCC.
|
